RHOC (Ras homolog family member C) is a small GTPase belonging to the Rho subfamily, which regulates cytoskeleton dynamics, cell motility, and intracellular signaling. It plays a critical role in cancer progression by promoting invasive and metastatic behaviors. RHOC activates downstream effectors like ROCK and LIM kinase to modulate actin polymerization, stress fiber formation, and cell contractility, facilitating tumor cell migration, invasion, and epithelial-mesenchymal transition (EMT). Overexpression of RHOC is linked to aggressive phenotypes in various cancers, including breast, lung, and ovarian malignancies, correlating with poor prognosis.
RHOC antibodies are essential tools for studying its expression, localization, and function in cancer biology. They enable detection of RHOC protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use these antibodies to explore RHOC's role in metastasis, drug resistance, and interactions with signaling pathways (e.g., TGF-β, Wnt). Additionally, RHOC is investigated as a potential therapeutic target, with inhibitors under preclinical study. However, its complex crosstalk with other Rho GTPases and context-dependent roles in tumor vs. normal tissues pose challenges for clinical translation. Validated RHOC antibodies remain crucial for elucidating its mechanisms in disease models.